Redefining
What is Possible
in Genetic Medicine
Delivering Impact Where It Matters Most
Our mission is to expand the potential of genetic medicine by overcoming current limitations. Through advanced tissue-targeting technologies, we strive to treat a wider range of diseases with systemically delivered therapies, offering renewed hope to patients with limited or no options.
Reaching untapped tissues
Evercrisp miniproteins are designed to access brain, kidney, muscle, and other tissues that have been previously unreachable by genetic medicines.
Enhancing safety
Evercrisp miniproteins do not require assisted delivery via LNPs, viral vectors, or other vehicles that can trigger immune responses.
Improving affordability
Scalable manufacturing reduces costs, making therapies more accessible to patients worldwide.
Platform
Evercrisp’s platform is built on machine learning-engineered miniproteins for receptor-mediated delivery of protein and oligonucleotide payloads directly into specific cells, to reach previously inaccessible tissues. And because our drug delivery approach does not rely on viral vectors, nanoparticles, or ex vivo cell manipulation, it holds the promise to enhance safety and broaden therapeutic applications for genetic medicines.
How Evercrisp’s Platform is Differentiated
Status Quo: Cellular Uptake of Oligonucleotide Therapeutics
Genetic medicines like ASOs and siRNAs can passively enter cells but require high doses to achieve effectiveness, impacting safety and efficacy.
Next Generation: Enhanced Cellular Uptake of Oligonucleotide Therapeutics
Evercrisp’s proprietary miniproteins enable ASOs and siRNAs to bind specific receptors, triggering active internalization and uptake by the targeted cell at safer doses.
This approach expands genetic medicine’s reach, enabling treatment of diseases previously beyond the scope of oligonucleotide therapies.
Status Quo: Delivery of Genome Editors Requires Viral or Non-Viral Delivery Vectors, or Transplantation of Genetically Modified Cells
Current gene editing approaches carry significant safety risks due to life-threatening immune reactions from delivery vectors, or lengthy hospitalization and safety risks from immune conditioning of patients treated with genetically modified cells. Further, genome editors cannot be directed to target tissues and are unable to be dosed repeatedly, greatly reducing the efficacy of current gene editing approaches.
Next Generation: Delivering Targeted Genome Editors Without Viral and Non-Viral Vectors
Evercrisp’s miniproteins enable cellular delivery of complex ribonucleoproteins like CRISPR/Cas9 to mediate precise genome editing in desired tissues. Our endosomal escape elements enhance cytosolic delivery, increasing genome editing efficiency.
Our self-delivering miniprotein and endosomal escape technology facilitates delivery to a broad range of tissues outside of the liver without the need for viral or non-viral vectors, allowing for safer, systemic, and repeatable dosing.
Our team
We are united by a shared vision to push the boundaries of science and deliver life-changing therapies. Together, we are redefining what’s possible in genomic medicine.
Founders
Jennifer Doudna, Ph.D.
read bio
Jennifer Doudna is a Nobel Laureate and Professor of Molecular and Cell Biology and Chemistry at UC Berkeley. Renowned as a pioneer in the CRISPR revolution, she co-founded transformative companies including Intellia, Caribou Biosciences, Mammoth, and Scribe. Jennifer’s groundbreaking work has redefined genomic editing and its therapeutic potential.
Tanja Kortemme, Ph.D.
read bio
Tanja Kortemme, a UCSF Professor in Bioengineering and Therapeutic Sciences, is a global leader in computational protein design. Her innovative work focuses on optimizing protein structures for therapeutic applications. A Chan Zuckerberg Biohub Investigator and a Fellow of the American Institute for Medical and Biological Engineering, Tanja brings cutting-edge protein design insights to Evercrisp’s mission. Tanja also serves on the board of Evercrisp Biosciences.
Spiros Liras, Ph.D.
read bio
Spiros Liras is a Venture Partner at Apple Tree Partners with extensive experience in leading R&D divisions at Biogen and Pfizer. As the co-founder of multiple biotech companies, including Nereid Therapeutics and Nine Square Therapeutics, and a practicing research scientist, Spiros has authored over 100 scientific publications and advanced drug discovery across diverse therapeutic areas. Spiros currently serves on the board of Evercrisp Biosciences as well as that of Apertor Pharmaceuticals, Deep Apple Therapeutics, Initial Therapeutics, Nereid Therapeutics, Nine Square Therapeutics, and Red Queen Therapeutics.
Management
Meenu Chhabra Karson, CEO
read bio
Meenu Chhabra Karson is a biopharmaceutical executive with over 20 years of leadership experience in driving strategic growth and innovation in life science organizations. She has served as a CEO since 2007 in multiple companies, both private and public, and has a proven track record of scaling organizations to advance value-generating milestones. Most recently, Meenu was the President and CEO of Proteostasis Therapeutics (NASDAQ: PTI) and led the company through a successful IPO to support advancing their pipeline of novel CFTR modulators and establishing the first ever personalized medicine registrational study in cystic fibrosis. Meenu also held key leadership roles at BioXell (SWX: BXLN) and Novartis, bringing deep expertise in corporate strategy and development. She has served on multiple boards and currently serves on the board of Evercrisp Biosciences as well as that of Macrogenics (NASDAQ: MGNX) where she is a member of the audit and compensation committees.
Geoffrey Berguig, CSO
read bio
Geoffrey Berguig is a seasoned biopharmaceutical executive with extensive experience in advancing therapeutic programs from discovery through approval. As the former Head of Chemistry and Drug Delivery at BioMarin Pharmaceutical Inc., he led the development of multiple programs, including adeno-associated virus (AAV) gene therapies as well as enzyme replacement, peptide and oligonucleotide therapeutics. Geoffrey has co-authored over 30 scientific publications and holds a Ph.D. in Bioengineering from the University of Washington. His expertise encompasses drug delivery systems, genetic medicines, and the translation of complex therapeutics into clinical applications.
Get
in Touch
please
contact us
for any
information